The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...
Initially, macular telangiectasia (MacTel) type 2 was considered a retinal vascular disease; however, over the past decade, studies have revealed that it is in fact a neurodegenerative condition ...
Long-term safety and efficacy of revakinagene taroretcel (NT-501) ciliary neurotrophic factor implant for macular telangiectasia type 2. Presented at: Retina 2025; Jan. 18-24, 2025; Koloa ...
GlobalData on MSN3mon
FDA delays priority review of Neurotech’s eye cell therapy implantThe company is seeking approval for the NT-501 implant as a treatment for macular telangiectasia type 2 ... cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback